Iradimed Corp. (IRMD), Friday revealed that the company expects fourth quarter preliminary unaudited revenue growth of 10 to 11 percent, to the range of approximately $19.2 million to $19.4 million.
For the full year, the company projects revenue of approximately $73.1 million to $73.3 million, compared to $65.6 million in the prior year for the full year 2024.
Currently, Iradimed's stock is trading at $57.25, down 1.65 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com